Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058405 | 1.00 | KEAP1 (0.33) | KEAP1NFE2L2HCAR2ALDH1A1 | |
| SCHEMBL5874735 | 0.97 | ALDH1A1 (0.35) | KEAP1NFE2L2HCAR2ALDH1A1 | |
| SCHEMBL5875212 | 0.97 | ALDH1A1 (0.35) | KEAP1NFE2L2HCAR2ALDH1A1 | |
| SCHEMBL1934761 | 0.95 | KEAP1 (0.33) | KEAP1NFE2L2HCAR2 | |
| SCHEMBL10992799 | 0.91 | HCAR2 (0.43) | HCAR2ALDH1A1 | |
| SCHEMBL3632775 | 0.91 | HCAR2 (0.43) | HCAR2ALDH1A1 | |
| SCHEMBL10859674 | 0.89 | HCAR2 (0.41) | HCAR2 | |
| SCHEMBL10859682 | 0.89 | HCAR2 (0.41) | HCAR2 | |
| SCHEMBL17695729 | 0.87 | NFE2L2 (0.52) | KEAP1NFE2L2HCAR2ALDH1A1 | |
| SCHEMBL20240604 | 0.86 | GSTP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867219-B1 | ASYMMETRICAL REVERSIBLE NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION | UNIV CORNELL (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2867219-A2 | ASYMMETRICAL REVERSIBLE NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION | Cornell University (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014210369-A2 | REVERSAL OF CYSTEINE-INACTIVATED NEUROMUSCULAR BLOCKING DRUGS WITH COMBINATIONS OF REVERSAL AGENTS | CORNELL UNIVERSITY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014005122-A2 | ASYMMETRICAL REVERSIBLE NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION | SAVARESE JOHN J (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20100292288-A1 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-4537893-A | TREATMENT OF PARKINSONS DISEASE, SEXUAL DYFUNCTION, ANXIETY, DEPRESSION OR HYPERTENSION | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292288-A1 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | HRH3, HRH4, HTR1D | KEAP1 753/4885NFE2L2 1851/4885HCAR2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.